by Naomi Pearce, Emily Bristow | Nov 5, 2020 | Uncategorized
Pharma Intelligence announced the Global Generics & Biosimilars Digital Awards Winners. Alvogen, Accord Healthcare, Aurobindo, STADA, Dr Reddy’s Laboratories, Samsung Bioepis, and Richard Saynor of Sandoz were among the winners.
by Bioblast Editor | Apr 23, 2020 | Other Updates, Uncategorized
On 23 April 2020, a presentation at the American Academy of Managed Care Pharmacy eLearning Days discussed future biosimilar launches in the US. A particular emphasis was placed on the number of adalimumab biosimilars waiting to come to market, with competition in...
by Naomi Pearce, Emily Bristow | Mar 19, 2020 | Uncategorized
On 19 March 2020, the Centre for Biosimilars reported on a pair of biosimilar bills which were introduced to the US Congress in the 2 weeks prior. These bills include a ‘shared savings’ model designed to encourage physicians to switch patients to...
by Naomi Pearce, Emily Bristow | Feb 28, 2020 | Uncategorized
Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch Amsparity (adalimumab) in the EU, citing unfavourable market conditions.
by Naomi Pearce, Emily Bristow | Feb 28, 2020 | Uncategorized
On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an anti-CTLA-4 antibody and candidate for the treatment of advanced solid tumours.
by Naomi Pearce, Emily Bristow | Feb 18, 2020 | Uncategorized
On 18 Feb 2020, BioPharma Reporter reported that AbbVie had outlined its defence strategy for Humira (adalimumab) competition in the US market. According to the BioPharma Reporter, AbbVIe CEO Gonzalez that explained AbbVie’s commercial US strategy will mimic the...
